TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06692140

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent(s)
Description: Percutaneous coronary intervention with Ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent(s)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PCI with Everolimus-eluting stents (durable polymer everolimus-eluting Xience or Promus stent(s))
Description: Percutaneous coronary intervention with Everolimus-eluting stents (durable polymer everolimus-eluting Xience or Promus stent(s))
Study: NCT04757116

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTind
Description: The iTind is implemented for 5-7 days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UroLift
Description: UroLift is a minimally invasive procedure where permanent implants are placed in the prostate.
Study: NCT05305560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin Tablets
Description: Daily ivermectin tablets intake for 28 days ; 200 mcg/kg on D1 then 100 mcg/kg daily from D2 to D28.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo tablets
Description: Daily placebo tablets intake for 28 days
Study: NCT06703034

Intervention type: OTHER
Group type: OTHER
Intervention: Biological Sampling
Description: The procedures specifically carried out for the study during a single visit are as follows:~* One nasopharyngeal swab for the baseline measurement of the nasal IFN-I score~* Venous blood sample collection in:~  * One yellow tube (5 mL) for anti-interferon antibody measurement~ * One PAXgene tube (2.5 mL) for the baseline IFN score without stimulation~ * Two green heparin tubes (8 mL) for performing immune-functional tests~ * Two large purple tubes (20 mL) for biological collection (if the patient provides specific consent)~ * A total of 35.5 mL of venous blood will be collected for the study during a single visit.~* Stool collection at home by the patient, to be sent by mail to the Northern Biological Resource Center (CRB) of the Hospices Civils de Lyon (HCL) within 10 days after the visit.~* A food frequency questionnaire composed of 159 items measuring the frequency of consumption of foods and drinks over the past 12 months to complement the analysis of the gut microbiota.

Intervention type: OTHER
Group type: OTHER
Intervention: Biological Sampling
Description: The procedures specifically carried out for the study during a single visit are as follows:~* One nasopharyngeal swab for the baseline measurement of the nasal IFN-I score~* Venous blood sample collection in:~  * One yellow tube (5 mL) for anti-interferon antibody measurement~ * One PAXgene tube (2.5 mL) for the baseline IFN score without stimulation~ * Two green heparin tubes (8 mL) for performing immune-functional tests~ * Two large purple tubes (20 mL) for biological collection (if the patient provides specific consent)~ * A total of 35.5 mL of venous blood will be collected for the study during a single visit.~* Stool collection at home by the patient, to be sent by mail to the Northern Biological Resource Center (CRB) of the Hospices Civils de Lyon (HCL) within 10 days after the visit.~* A food frequency questionnaire composed of 159 items measuring the frequency of consumption of foods and drinks over the past 12 months to complement the analysis of the gut microbiota.
Study: NCT05716035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab Injection
Description: Participants will receive IV tocilizumab
Study: NCT04628962

Intervention type: PROCEDURE
Intervention: Collection and Raman analysis of saliva for the database
Description: Saliva will be collected and processed for the Raman analysis. The collected data will be computed for the creation of the classification model

Intervention type: PROCEDURE
Intervention: Collection and Raman analysis of saliva for the database
Description: Saliva will be collected and processed for the Raman analysis. The collected data will be computed for the creation of the classification model

Intervention type: PROCEDURE
Intervention: Collection and Raman analysis of saliva for the database
Description: Saliva will be collected and processed for the Raman analysis. The collected data will be computed for the creation of the classification model

Intervention type: PROCEDURE
Intervention: Collection and Raman analysis of saliva for the database
Description: Saliva will be collected and processed for the Raman analysis. The collected data will be computed for the creation of the classification model

Intervention type: PROCEDURE
Intervention: Collection and Raman analysis of saliva for the database
Description: Saliva will be collected and processed for the Raman analysis. The collected data will be computed for the creation of the classification model

Intervention type: PROCEDURE
Intervention: Collection and Raman analysis of saliva for the database
Description: Saliva will be collected and processed for the Raman analysis. The collected data will be computed for the creation of the classification model
Study: NCT04593901

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Video and App Review
Description: Scenario Review: The scripts and/or videos will be iteratively reviewed by individual and small groups of home healthcare personnel using Zoom, Microsoft Teams, or similar. The participants will review scripts and/or recordings of the scripts and discuss how well each situation has been represented, how to improve it, and whether it is applicable in their agency.~App Review: Following review of the scenarios, participants will review the smartphone app currently under development, including the control buttons, their placements, and other features of the screen interface. The first 9-12 participants (approximately) will be asked to provide feedback on the app's layout, control locations, and overall appearance. Once suggested changes have been made, the app will then be reviewed by the remaining participants for final review and usability assessment.
Study: NCT05493059

Intervention type: OTHER
Intervention: Data collection
Description: o Retrospective data collection in database from medical records (clinical, parasitological and therapeutic data)

Intervention type: OTHER
Intervention: Questionnaires
Description: o Administration of two standardized questionnaires by telephone in prospective:~* Dermatology Life Quality Index (DLQI)~* Treatment Satisfaction Questionnaire for Medication (TSQM)
Study: NCT05871073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% Injectable Solution
Description: WOUND INFILTRATION AFTER SPINAL SURGERY

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% Injectable Solution
Description: WOUND INFILTRATION AFTER SPINAL SURGERY

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone 8mg
Description: WOUND INFILTRATION AFTER SPINAL SURGERY
Study: NCT05430373

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: GT101
Description: Autologous tumor infiltrating lymphocyte injection
Study: NCT06726031

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: wearing VR glass
Description: The intervention is the application of VR headsets during the procedure for patients who were previously indicated for transradial coronary angiography and were randomized to the VR headset group.
Study: NCT05162872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib，Sintilimab
Description: Niraparib 200 mg QD D1-21 Sintilimab 200 mg IV q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib，Sintilimab
Description: Niraparib 200 mg QD D1-21 Sintilimab 200 mg IV q3W
Study: NCT05650372

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity resistive exercise
Description: Participants of this group will be applied manual lymphatic drainage and compression bandaging every day of the week, and they will exercise for 25 minutes, three sets of each exercise at 80% intensity of 1 max repetition, 2 days of the week. Exercise training consist of warm-up and cool-down (10-15 repetitions of range of motion and 10 minutes of active stretching exercises) and resistive exercises.Each of the experimental sessions involved resistance exercises targeting all the major muscle groups in the upper body. Specifically, the exercises included the chest press, lat pull-down, bicep curl, triceps extension, lateral raise, and wrist curl.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low intensity resistive exercise
Description: participants in this group will be applied manual lymphatic drainage and compression bandaging every day of the week and they will exercise for 25 minutes, three sets of each exercise at 30% intensity of 1 max repetition 2 days of the week.~Exercise training consist of warm-up and cool-down (10-15 repetitions of range of motion and 10 minutes of active stretching exercises) and resistive exercises. Each of the experimental sessions involved resistance exercises targeting all the major muscle groups in the upper body. Specifically, the exercises included the chest press, lat pull- down, bicep curl, triceps extension, lateral raise, and wrist curl.
Study: NCT06391463

Intervention type: OTHER
Intervention: Carriage of MRB ou BC
Description: Study of the epidemiology of the carriage of BMR and BC germs in patients in the neonatology department
Study: NCT06726226

Intervention type: OTHER
Intervention: Standard care for preterm infants
Description: Standard care for preterm infants according to the institutional protocol
Study: NCT06725823

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: suprascapular nerve block group
Description: A volume of (10 ml) of 2% lidocaine (2ml), 3% Mepivacaine (2ml), 1 ml methyl-prednisolone acetate (40 mg) and dextrose 5% (5ml) will be injected to both groups.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: shoulder anterior capsular block group
Description: A volume of (10ml) of 2% lidocaine (2ml), 3% Mepivacaine (2ml), 1 ml methyl-prednisolone acetate (40 mg) and dextrose 5% (5ml) will be injected to both groups.
Study: NCT06725888

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagitab -T vaginal tablets. Components: tyndallized probiotic L. plantarum HA-119, lactic acid, and xylo-oligosaccharides, lauryl glucoside, and macrogol 3350:
Description: Vagitab -T will be used for 3 monthly cycles of 10 days each. Metronidazole will be used for 1 cycle of 7 days at the start of the study~Metronidazole will be administered as follows:~500 mg intravaginally once per day for 7 days or 500 mg orally 2 times/day for 7 days
Study: NCT06726330

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fimbriectomy Followed by Delayed Oophorectomy (F-DO)
Description: This intervention involves two stages:~1. Fimbriectomy: A preventive surgical procedure that removes the fimbrial end of the fallopian tubes, including adjacent ovarian tissue, while preserving ovarian function to avoid premature menopause.~2. Delayed Oophorectomy: The removal of ovaries, performed at menopause or later, depending on patient preference and clinical guidelines.~   * The F-DO strategy aims to reduce the risk of tubo-ovarian or primary peritoneal carcinoma, which often originates in the fallopian tubes, while minimizing the adverse effects of premature menopause such as cardiovascular disease and osteoporosis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Salpingo-Oophorectomy
Description: This standard surgical intervention involves the removal of both fallopian tubes and ovaries (BSO) to eliminate the risk of tubo-ovarian or primary peritoneal carcinoma. It is typically recommended for women with a genetic predisposition (e.g., BRCA1/2 mutations) around the age of 40-45. While highly effective in preventing cancer, BSO induces premature menopause, which may result in long-term side effects such as increased cardiovascular risk, osteoporosis, and cognitive decline.
Study: NCT06726980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dextrose 5%
Description: patients will receive 5 % dextrose infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose 10%
Description: patients will receive 10 % dextrose infusion (25gm/ 250 mL)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: patients will receive infused IV 0.9 % saline
Study: NCT06726096

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection
Description: The drug was administered once every 4 weeks.~Other Names:~Tocilizumab Injection placebo control

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection
Description: The drug was administered once every 4 weeks.~Other Names:~Tocilizumab Injection placebo control

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection
Description: The drug was administered once every 4 weeks.~Other Names:~Tocilizumab Injection placebo control
Study: NCT06726291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEPA (300mg netupitant/0.5mg palonosetron)
Description: a single dose (capsule) of NEPA (300mg netupitant/0.5 palonosetron) at day 1 for a maximum of 4 cycles
Study: NCT06378112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTO®
Description: After teeth extraction, a guided bone regeneration procedure will be performed using a bone graft and a soft collagenated cortical membrane as graft stabilizer. Implant placement surgery will also be performed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GTO®
Description: After teeth extraction, a guided bone regeneration procedure will be performed using a bone graft and a soft collagenated cortical membrane as graft stabilizer. Implant placement surgery will also be performed.
Study: NCT06726525

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HPMC+GlicoPro eyedrops
Description: HPMC+GlicoPro eyedrops, artificial tears for dry eye disease

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxypropyl-methylcellulose
Description: Hydroxypropyl-methylcellulose eyedrops, artificial tears for dry eye disease
Study: NCT05042583

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Stellate ganglion block
Description: The probe direction was 30-45 degrees from the sagittal plane of the neck. The anterior nodules of the transverse process of the sixth cervical vertebra were displayed. The important anatomical structures were distinguished, and the internal carotid artery and longus cervical muscle were observed. A 25G, 6cm puncture needle was used with the tip beveled downward, and the needle path and tip were shown under ultrasound. The tip reached the high-echo sieve structure between the carotid artery and longus cervical muscle, and the drug solution was injected after withdrawal without blood and gas . The experimental group was injected with 6ml 0.5% ropivacaine.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block
Description: The probe direction was 30-45 degrees from the sagittal plane of the neck. The anterior nodules of the transverse process of the sixth cervical vertebra were displayed. The important anatomical structures were distinguished, and the internal carotid artery and longus cervical muscle were observed. A 25G, 6cm puncture needle was used with the tip beveled downward, and the needle path and tip were shown under ultrasound. The tip reached the high-echo sieve structure between the carotid artery and longus cervical muscle, and the drug solution was injected after withdrawal without blood and gas . The experimental group was injected with 6ml 0.5% ropivacaine.
Study: NCT05144139

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 mRNA vaccine
Description: Intramuscular injection, COVID-19 mRNA vaccine/placebo, 21 days interval

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: COVID-19 mRNA vaccine
Description: Intramuscular injection, COVID-19 mRNA vaccine/placebo, 21 days interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 mRNA vaccine
Description: Intramuscular injection, COVID-19 mRNA vaccine/placebo, 21 days interval

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: COVID-19 mRNA vaccine
Description: Intramuscular injection, COVID-19 mRNA vaccine/placebo, 21 days interval
Study: NCT04291573

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HD-tDCS
Description: Real stimulation (2mA, 20min) with anode on C3/C4 of the lesioned hemisphere and 4 return electrodes \~4cm away

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham HD-tDCS
Description: Sham stimulation (2mA, ramp up and down phases of 30s) with anode on C3/C4 of the lesioned hemisphere and 4 return electrodes \~4cm away
Study: NCT05187819

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: predictive value of a blood test
Description: Evaluation of the clinical value of a new blood based test for diagnosis of Alzheimer's disease in a general practice population.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: predictive value of a blood test
Description: Evaluation of the clinical value of a new blood based test for diagnosis of Alzheimer's disease in a general practice population.
Study: NCT06340035

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: The TENS group is subjected to transcutaneous current. Two surface electrodes are inserted at the level of the superior gluteal and inferior gluteal nerve tract. A protocol of 10 stimulations x 10 seconds of stimulations x 10 times is performed with a 10 second rest between each repetition. A maximum contraction evoked without pain is sought.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Percutaneous Peripheral Nerve Stimulation
Description: In the pPNS group, the superior gluteal nerve and inferior gluteal nerve are stimulated percutaneously. The nerves are localized at an ultrasound-guided level and with respect to the vascular-nervous package two acupuncture needles are inserted, one for each nerve. The stimulation is the same as the TENS group: 10 stimulations x 10 times x 10 seconds, evoking the maximum contraction without pain.
Study: NCT06089720

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zinc oxide nanoparticle coated orthodontic molar tubes (experimental)
Description: nine orthodontic patients each one will receive 2 coated zinc oxide nanoparticle molar tubes in split-mouth manner and will assess for antimicrobial effect on s. mutans \& lactobacillus after two weeks, in addition to evaluation of bond failure rate after three months.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: orthodontic molar tubes (control)
Description: nine orthodontic patients each one will receive two uncoated molar tubes in split-mouth manner and will assess for antimicrobial effect on S. mutans \& lactobacillus after two weeks, also, evaluation of the bond failure rate after three months period.
Study: NCT05867147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vanzacaftor
Description: Tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vanzacaftor Placebo
Description: Placebo for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vanzacaftor Placebo
Description: Placebo for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vanzacaftor Placebo
Description: Placebo for oral administration.
Study: NCT04993547

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Parent and peer presence
Description: Does the presence of fellow pupils and parents improves a pupil's resistance to undergo a nasopharyngeaal swab test?
Study: NCT05867147

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Tablets for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Tablets for oral administration.
Study: NCT04993547

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Parent and peer presence
Description: Does the presence of fellow pupils and parents improves a pupil's resistance to undergo a nasopharyngeaal swab test?

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Parent and peer presence
Description: Does the presence of fellow pupils and parents improves a pupil's resistance to undergo a nasopharyngeaal swab test?

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parent and peer presence
Description: Does the presence of fellow pupils and parents improves a pupil's resistance to undergo a nasopharyngeaal swab test?
Study: NCT04908787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BD0801
Description: Subjects receive BD0801 , intravenously, d1, d15, q4w, Dosage form: injectable, Strength: 1.5 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Subjects receive Weekly Paclitaxel, intravenously, d1, d8, d15, d22, q4w, Dosage form: injectable, Strength: 80 mg/m2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Subjects receive Weekly Paclitaxel, intravenously, d1, d8, d15, d22, q4w, Dosage form: injectable, Strength: 80 mg/m2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects receive Placebo, intravenously, d1, d15, q4w, Dosage form: injectable, Strength: 1.5 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Subjects receive Topotecan, intravenously, d1, d8, d15, q4w, Dosage form: injectable, Strength: 4mg/m2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topotecan
Description: Subjects receive Topotecan, intravenously, d1, d8, d15, q4w, Dosage form: injectable, Strength: 4mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin liposome
Description: Subjects receive doxorubicin liposome, intravenously, d1, , q4w, Dosage form: injectable, Strength: 40mg/m2
Study: NCT06357897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local PEG4000
Description: PEG-Chula is developed from PEG 4000 used at King Chulalongkorn Memorial Hospital with added sweetener and flavours. Children will be given PEG-Chula at a dose of 0.5 - 1 g/kg/day.

Intervention type: DRUG
Group type: OTHER
Intervention: Commercial PEG4000
Description: For commercial PEG, We use Forlax as the control group. Children will be given Forlax at a dose of 0.5 - 1 g/kg/day.
Study: NCT04108286

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1-DAY ACUVUE MOIST
Description: TEST

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1-DAY ACUVUE MOIST
Description: TEST

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DAILIES AQUA COMFORT PLUS
Description: CONTROL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DAILIES AQUA COMFORT PLUS
Description: CONTROL
Study: NCT05867147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Placebo
Description: Tablets for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin Placebo
Description: Tablets for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin Placebo
Description: Tablets for oral administration.